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Abstract. The primary treatment of acromegaly remains
transsphenoidal adenomectomy, yet the tissue overgrowth
of acromegaly often progresses following surgery, and
responds to radiotherapy only after significant delay.
Persistently elevated serum growth hormone (GH) and
insulin-like growth factor-I (IGF-I) concentrations can be
normalized in about half of post-surgery acromegalics using
the pharmacologic alternatives presently available, the
dopamine agonists (DA) and somatostatin (SST) analogs.
Cabergoline, the most efficacious DA, normalizes IGF-I in
approximately 37% of patients, whereas the long-acting
SST analogs, Octreotide LAR and Lanreotide SR, do so
in 66%. Significant tumor shrinkage may be attained with
SST analogs in particular, and when necessary, the primary
medical treatment of acromegaly may be successfully
addressed with this class of drugs. Greatly enhanced
efficacy is expected from the GH receptor antagonist
pegvisomant, which is nearing market availability and
will enable the normalization of serum IGF-I in virtually
all patients treated. We review here the pharmacologic
treatments of excessive GH secretion.
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Introduction
Acromegaly, a syndrome of tissue overgrowth that re-
sults from high concentrations of circulating insulin-
like growth factor I (IGF-I) is, in the vast majority of
cases, a consequence of the hypersecretion of growth
hormone (GH) from a benign monoclonal adenoma of
pituitary somatotropes [1]. GH-secreting adenomas ac-
count for about 10 percent of all pituitary tumors that
come to medical attention [2,3]. Though the disease is
uncommon, with an estimated prevalence of 40 to 50
per million population, it is believed to be widely under-
diagnosed due to its insidious nature and a general low
level of disease awareness in the medical community.
As a result, despite the well-described features of the
syndrome, patients often live with active disease for up
to 10 years before a diagnosis is made [4]. When sus-
pected on clinical grounds, the diagnosis of acromegaly
is relatively straightforward and is confirmed by ele-
vated age- and sex-adjusted serum IGF-I with GH that
fails to suppress to less than 1 ng/mL after oral glu-
cose challenge. The common co-morbidities of diabetes
mellitus, hypertrophic cardiomyopathy, hypertension
and hypopituitarism decrease the life expectancy of
patients with acromegaly by an average of 10 years
[5]. Cancer-related mortality is increased, as reported
by Orme et al. [6] in a series of 1362 patients with
acromegaly, particularly in patients with colon can-
cer and in those with post-treatment GH levels above
2.5 ng/mL. The overall incidence of cancer does not ap-
pear to be affected [6].
Surgical excision via transsphenoidal approach re-
mains the preferred primary treatment of GH-secreting
adenomas. Ongoing postoperative surveillance is nec-
essary, as the strict normalization of circulating GH and
IGF-I requires aggressive secondary treatment in greater
than half of patients. Surgeons with extensive experi-
ence in excising GH-secreting microadenomas (<10 mm
in diameter) report cure rates between 60 and 90 per-
cent [7–10] though this success rate represents the very
best outcome, and is not likely matched by surgeons
with less experience in pituitary microsurgery. More-
over, fewer than one third of GH-secreting tumors are
less than 10 mm in diameter at diagnosis, and GH se-
cretion from a macroadenoma is normalized by surgery
alone in less than half of cases [7–10].
Adjunctive treatment in the form of fractionated ex-
ternal beam radiotherapy, typically 40–50 Gy delivered
over a 5–6 week period, is commonly used, although the
benefits of radiotherapy can be offset by serious com-
plications including the onset of hypopituitarism which
occurs in 30 to 70 percent of patients in the decade
after treatment [11–13]. The delay between radiation
treatment and normalization of GH secretion, which
can range from 5 to 10 years, means patients continue
to face active acromegaly for considerable time after
treatment, necessitating the use of adjunctive medical
treatment. Finally, the reported rates of normalization
of IGF-I following radiotherapy are widely disparate,
from 5 to about 70 percent [13–16], and other risks
such as vascular damage and secondary neoplasms,
though rare, should be weighed against the potential
benefits. Stereotactic radiosurgery employing gamma
knife, proton beam, or LINAC, may decrease these
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adverse effects [17–19] but is available in relatively few
centers.
The prospect of effective management of acromegaly
through medical treatment has come within reach of
increasingly more patients since the introduction of
dopamine agonist therapy for GH-suppression in the
1970’s. Presently, the long-acting analogs of somato-
statin offer the best efficacy of the GH-suppressive
agents; IGF-I may be normalized in up to two thirds
of postoperative acromegaly patients treated with oc-
treotide LAR. We review here the two modalities of med-
ical treatment of acromegaly relied upon most in the past
three decades—dopamine agonists, with particular at-
tention to cabergoline, and somatostatin analogs, with
emphasis on the long-acting formulations. Lastly, early
reports of the clinical efficacy of the forthcoming GH
receptor antagonist, pegvisomant, are reviewed.
Background
Several clinical goals must be addressed by any strat-
egy for the treatment of acromegaly, including the re-
lief of symptoms of tissue overgrowth, the alleviation
of tumor mass effects while preserving or restoring nor-
mal pituitary function, the normalization of circulating
IGF-I, and, ultimately, the normalization of mortality.
Though GH secretion may remain elevated, some miti-
gation of symptoms, particularly of arthralgias, can oc-
cur with any significant decrease in IGF-I levels [20]. In
the assessment of surgical outcome, the lowest random
or fasting serum GH level achieved postoperatively has
generally been accepted as an indicator of biochemical
status. Normalization of the mortality rate associated
with acromegaly has been demonstrated when random
GH levels of less than 2.5 ng/mL [4,21], and even of less
than 5 ng/mL are reached [9,22], though these levels
do not necessarily indicate normalized GH secretion.
While the definition of normal GH secretory dynamics
has become increasingly rigorous, the biochemical def-
inition of ‘cured’ acromegaly has concurrently become
less certain. Newer, more sensitive assays for GH and
IGF-I have enabled the detection of persistently, albeit
mildly, abnormal GH secretion following surgery, mak-
ing the question of what constitutes normalized GH se-
cretion debatable [23–25]. Postoperative GH secretion
may remain abnormal in many patients when assessed
by oral glucose suppression and employing a sensitive
GH assay [26,27]. Still, a window of ‘safe’ GH secretion
may be identified. Based on an analysis of the GH re-
sponses to an oral glucose tolerance test (OGTT) in 32
patients with treated acromegaly compared with those
in 56 normal control subjects, Costa et al. [27] advocated
the criterion of glucose-suppressed GH to under 1 ng/mL
as indicative of safe GH secretion, a conclusion which
supported previously published recommendations [28].
Growth hormone dynamics alone must not be relied
upon to accurately represent disease status, however.
Serum IGF-I has emerged as a more reliable biochemical
marker of GH effect at the tissue level [26–31]. Though
the circulating concentration of serum IGF-I is affected
by nutritional state, hepatic function, age, and gender,
in addition to the GH secretory status, it is a very reli-
able reflection of overall 24-hour GH-tissue effect. When
measured using a well-validated assay with age- and sex-
specific normative data, IGF-I is the best and most cost-
efficient marker for assessing the adequacy of treatment
of acromegaly, and should be the preferred marker for
assessing biochemical cure.
The lowering of IGF-I has been associated with re-
ductions in acromegaly-related mortality [26] yet ques-
tions surrounding the GH/IGF-I relationship remain to
be answered, as normalization of IGF-I may still be ac-
companied by persistently abnormal secretory GH dy-
namics [26,27]. Conversely, abnormal GH secretion as
assessed by OGTT suppression or mean 24-hour GH, ap-
plying currently accepted norms, may not always corre-
late with the finding of elevated IGF-I, as recently shown
by Dimaraki et al. [32]. In this study, 16 patients with
clinical features of acromegaly and serum IGF-I levels
that were elevated for age- and sex-matched controls,
had mean 24-hour GH levels less than 2.5 ng/mL, within
the previously accepted normal range for healthy adults.
Eight patients also had glucose-suppressed GH levels
under 1 ng/mL, yet GH-producing pituitary adenomas
were identified histologically in surgical specimens from
13 of 14 patients. These findings show that IGF-I and GH
results can be discrepant, and cast further doubt on the
merit of using dynamic GH testing alone in the diag-
nosis or follow-up of acromegaly. The measurement of
serum IGF-I in a sensitive assay with established age-
and sex-adjusted normal ranges is of chief importance
in the assessment of surgical or medical treatment.
Dopamine Agonists
Although dopamine agonists are considerably less ef-
fective in decreasing GH hypersecretion in acromegaly
than they are in subduing hyperprolactinemia, cabergo-
line is frequently useful in the treatment of acromegaly
with concomitant prolactin hypersecretion, and is a
valid agent in the medical treatment of GH hypersecre-
tion. Up to 40% of GH-secreting adenomas co-secrete
prolactin [33], and dopaminergic D2 receptors are ex-
pressed by some somatotropes [34,35]. Dopamine is a
catecholamine neurotransmitter with diverse functions,
including the regulation of some neuroendocrine sys-
tems. Dopamine restrains prolactin secretion and stim-
ulates GH release in healthy subjects, though it para-
doxically suppresses GH release in some patients with
acromegaly [36,37]. The dopamine agonists currently
available in the United States, bromocriptine, pergolide,
and cabergoline, are synthetic derivatives of ergot alka-
loids originating in the fungus Claviceps sp. [38], and
have been used in the treatment of acromegaly since
bromocriptine was first introduced in the mid-1970s
[39].
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In acromegaly, as 24-hour GH secretion increases,
serum IGF-I levels show a parallel rise until a GH con-
centration of 10–20 ng/mL is reached, at which point
IGF-I concentrations plateau [30]. Therefore, though
serum GH concentrations may fall significantly under
the inhibition of a dopamine agonist or other medica-
tion, IGF-I levels are unimproved if the mean GH con-
centration remains above 10–20 ng/mL. In light of this,
many of the early efficacy studies of bromocriptine in
acromegaly are difficult to interpret as they assessed
outcome based on percent suppression of GH from
baseline levels. A 1994 review of 31 published studies
of bromocriptine involving a total of 549 patients with
acromegaly and using daily doses of 5 to 80 mg demon-
strated an overall success rate (defined as suppression
of GH to less than 5 ng/mL) of 20%, while IGF-I was
normalized in a mere 10% of patients [38].
There are few published studies of pergolide for the
treatment of acromegaly. A review of the medical lit-
erature published in English yields two small studies
involving a total of 15 patients with acromegaly treated
with daily doses of pergolide of 100 to 1500 mcg orally,
over 4 to 31 months. Combining these studies, pergolide
suppressed GH to an average of 50% of baseline, while
just 27% (4 of 15) patients reached a serum GH less than
5 ng/mL [40,41]. In these studies, IGF-I normalization
was not reported.
Cabergoline (Dostinex©R, Pharmacia Corp., Peapack,
New Jersey, USA) is a dopamine agonist with more
specific D2 receptor binding capacity than bromocrip-
tine, and is currently the best of this class of drugs for
the treatment of both prolactin- and GH-secreting pi-
tuitary adenomas. The serum half-life of cabergoline is
about 65 hours, allowing oral administration just once
or twice per week [42], which, with its better tolerabil-
ity in comparison with bromocriptine, enhances patient
compliance. In the first multicenter trial of cabergoline
in acromegaly, Abs et al. administered cabergoline to 64
patients and followed them from 3 to 40 months [43].
Cabergoline was initiated at a dose of 0.5 mg twice
weekly. By study end, the weekly dose was 1.75 mg
(0.5 mg every two days) or less in 87% of patients. Serum
IGF-I was lowered to less than 300 ng/mL in 50% (8/16) of
patients with prolactin co-secretion, and in 35% (17/48)
of patients without concomitant hyperprolactinemia.
Patients with a pre-treatment serum IGF-I under
750 ng/mL showed the most vigorous response. Random
serum GH was lowered to less than 5 ng/mL in 73% of
patients, and to less than 2 ng/mL in 46%. Cozzi et al. [44]
reported the effect of cabergoline in a smaller study of 18
acromegaly patients over 6 months of treatment. Serum
IGF-I levels were normalized in 5 of 18 patients, while
mean IGF-I decreased from 720 ng/mL to 375 ng/mL.
Mean basal GH decreased from 6.6 ng/mL before treat-
ment to 3.5 ng/mL afterwards. Combining these two
studies, serum IGF-I was normalized in 36.6% (30/82)
of patients, and pituitary adenoma size was reduced in
66.7% (16/24). Cabergoline is generally well tolerated
[43,44].
Though the treatment of acromegaly is an unap-
proved use of this drug, cabergoline has succeeded in
renewing interest in the GH-suppressive treatment of
acromegaly via activation of dopamine D2 receptors.
Cabergoline offers the best efficacy of the dopamine ag-
onists in the medical treatment of acromegaly, inducing
a normalized serum IGF-I in approximately one third of
patients, and in a higher percentage of those with pro-
lactin co-secretion. In light of its superior side effect pro-
file in comparison with bromocriptine and its lower cost
in comparison with the somatostatin analogs, cabergo-
line is a legitimate first choice for adjuvant postoperative
treatment of persistent GH hypersecretion, particularly
in the patient with concurrent hyperprolactinemia.
Somatostatin Analogs
The somatostatin (SST) peptides are cyclic proteins 14
and 28 amino acids in length, which act on a diverse
array of tissues in regulatory and suppressive functions.
Cells that produce SST are scattered throughout the
peripheral and central nervous systems, the gastroin-
testinal tract, and the immune system. Among the
endocrine functions of SST are the suppression of
insulin and glucagon secretion in the pancreatic islets,
and the suppression of TSH and GH in the anterior
pituitary [45–47]. Somatostatin-14 was first discovered
in rat hypothalamus as an inhibitor of GH secretion
[48]; its amino-terminal extended congener, SST-28 was
described several years later [49]. The multiple func-
tions of somatostatin and its ubiquitous distribution is
dependent on an array of heterogeneous cell-surface
receptors, and on their unique patterns of tissue
expression. Five G-protein coupled, transmembrane
somatostatin receptor (SSTR) isoforms were identified
and characterized in the 1990’s [50–52], all of which
feature the familiar design of 7 cell membrane-spanning
domains. Intracellular post-receptor effects occur
through inhibition of intracellular [cAMP] and [Ca2+]
via functional connection between the receptor and
adenylate cyclase, and cell-surface potassium and cal-
cium ion channels, respectively [47]. Receptor subtypes
2 and 5 (SSTR-2 & SSTR-5) are the predominate recep-
tors found on the surface of pituitary somatotropes.
Somatotrope adenomas may express SST receptors
in higher density than surrounding normal pituitary
[53], and the ratio of SSTR2/SSTR5 mRNA transcripts
among GH-producing adenomas is highly variable [54].
Some tumors express neither receptor subtype [55],
or express mutant SST receptors [56], and are thereby
resistant to treatment with SST analogues.
The potential utility of a pharmacologic agent
with somatostatin-like activity in the treatment of
acromegaly is readily apparent. The half-life of native
somatostatin in serum is less than 3 minutes, a prop-
erty that would necessitate its delivery by constant in-
fusion to achieve lasting, significant suppression of GH.
Furthermore, its rapid decline in serum is followed by
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rebound hypersecretion of GH, insulin, and glucagon
[57]. Therefore, the need for a more enduring synthetic
ligand able to bind and activate SSTR-2 and SSTR-5 with-
out rebound effects was evident to early researchers.
The development of the synthetic somatostatin
analogs—octreotide and lanreotide—has overcome the
pharmacokinetic challenges of native somatostatin.
Both compounds are octapeptide molecules with
binding affinity directed towards SSTR-2. The GH-
suppressive effectiveness of octreotide is 45 times that
of native somatostatin-14 [58], and its serum half-life af-
ter s.c. injection is about 100 minutes. Octreotide is usu-
ally given in three daily s.c. injections, in total daily doses
of 300–750 mcg, though up to 1500 mcg per day is some-
times necessary. GH secretion is rapidly suppressed af-
ter a single s.c. injection of octreotide, with a maximal
effect between 2 and 6 hours after injection [59].
Early studies of octreotide therapy in small numbers
of acromegaly patients were promising [60–63], and in
a multicenter trial of s.c. octreotide in 189 patients fol-
lowed from one to 33 weeks, serum GH was reduced to
under 5 ng/mL in 45% [64]. In an attempt to differentiate
nonresponders from those patients who will ultimately
benefit from prolonged octreotide treatment, GH re-
sponse to acute testing with 100 mcg s.c. octreotide has
been used [65], but has been shown to be of less value
in predicting responsiveness than either one month of
octreotide treatment or pre-treatment 111In-pentreotide
scintigraphy for evaluation of the presence of tumor
SSTR expression [66].
As a thrice-daily subcutaneous injection, octreotide
poses the potential problem of noncompliance; the en-
capsulation of octreotide and lanreotide within slowly
dissolving biodegradable polymer microspherules has
provided for greater ease of compliance by allowing
drug delivery by intramuscular depot injections. Within
one hour after a single i.m. injection of long-acting
release (LAR) octreotide (Sandostatin©R LAR©R, Novar-
tis Pharmaceuticals, East Hanover, New Jersey, USA),
serum octreotide levels show a brief rise as the drug
coating the surface of the microspherules enters the cir-
culation. After a rapid fall, the serum concentration then
rises again between 7 and 14 days after injection, and re-
mains at a plateau for another approximately 19 days,
before gradually tapering off [67]. The duration of effect,
but not the potency of GH-suppression, is augmented
by increasing doses. Monthly (every 4 weeks) i.m. in-
jections allows for octreotide levels sufficient for con-
stant GH-suppression to be maintained [68], although
adequate control may also be maintained on a q 6 week
injection regimen in some patients [69].
Somatuline©R LA (Beaufour Ipsen, Paris, France), the
slow-release lanreotide, is also a microencapsulated
compound, and is given by depot injection every 10 to
14 days [70]. A new form of lanreotide, a deep s.c. ad-
ministered gel preparation (Somatuline©R Autogel©R ) has
been introduced in clinical studies and can be injected
monthly [71]. Somatuline LA and Somatuline Autogel
are approved for use in some European countries.
Most acromegaly patients treated with analogs of so-
matostatin show a significant decrease in serum GH and
IGF-I levels. In a review of published outcomes [72],
Freda reported that serum levels of IGF-I were lowered
to the normal range in an average of 66% of patients
treated with octreotide LAR (in 6 combined studies),
and in an average of 48% of patients treated with lan-
reotide SR (in 13 studies). GH was suppressed in an
average of 56% of patients treated with octreotide LAR
(compiling data from 7 studies), and in an average of
49% of patients treated with lanreotide SR (in 12 stud-
ies). Across the various studies, wide variability in out-
comes is reported, probably as an effect of differences
in length of follow-up, drug doses, and criteria employed
in the assessment of GH status. As observed by Freda,
most studies examining the efficacy of octreotide LAR
analyzed response to treatment in patients preselected
for response to s.c. octreotide, and therefore the data on
LAR therapy may not accurately reflect response rates
in a de novo population.
Somatostatin analog treatment is associated with
some degree of reduction in tumor volume in at least
30% of patients [72]. Subcutaneous octreotide has been
reported to decrease macroadenoma volume by about
75% in one case report [73] and by 20 to 54 percent when
given pre-operatively in a small group of patients [74].
Indeed, most studies report a decrease in tumor volume
of between 20 and 50 percent as assessed in the review
by Freda[72], in which data from fifteen studies of long-
acting preparations and s.c. octreotide were gathered.
The effect of octreotide on tumor size is reportedly due
to a direct reduction in cell volume or number, as op-
posed to an anti-angiogenesis effect [75].
Preoperative somatostatin analog treatment is re-
ported to improve the acromegaly patient’s general con-
dition for pituitary surgery, and should theoretically im-
prove surgical remission rates by shrinking or soften-
ing the tumor, making more complete resection easier
to achieve [64,76–78]. Yet it remains uncertain whether
this is in fact the case, as studies addressing the question
are contradictory. Two prospective, randomized studies
involving a total of 62 patients could detect no benefit
of preoperative s.c. octreotide on rates of postoperative
normalization of GH or IGF-I, or duration of hospital
stay after surgery [79,80]. On the other hand, a retro-
spective analysis of 22 patients treated pre-operatively
with s.c. octreotide, and compared with 37 patients left
untreated before surgery demonstrated improvements
in ECG tracings, blood pressures, and glucose and lipid
profiles, which were associated with shorter hospital
stays postoperatively [81]. Most importantly, the surgi-
cal cure rate, as defined by normalized IGF-I, was nearly
twice as high in the octreotide-pretreated group as in the
controls (54.5% vs. 29.7%, p < 0.005). Improvements in
the surgical cure rates in octreotide-pretreated patients
were also reported by two other groups [82,83], but these
improved outcomes were mainly limited to intrasellar
macroadenomas. Thus, the ultimate value of octreotide
pretreatment is still not certain.
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The beneficial affects of somatostatin analogs on car-
diovascular performance in patients with acromegaly
have been examined in detail in two prospective studies.
Subcutaneous octreotide increased left ventricular ejec-
tion fraction and exercise workload, and improved exer-
cise duration while decreasing heart rate and blood pres-
sure in 30 acromegalic patients investigated by Colao
et al. over a period of one year [84]. In a similar study
of 15 octreotide-naı̈ve patients treated with octreotide
LAR for 6 months, left ventricular mass index (LVMi), in-
terventricular septum thickness, and LV posterior wall
thickness were improved in all patients after 3 and 6
months of treatment [85]. Six of eleven patients with
left ventricular hypertrophy at study entry normalized
their LVMi while on treatment. These positive cardiovas-
cular effects were generally seen to occur more slowly
in older patients with longer disease duration [85].
Somatostatin analogs appeared to prolong the time
necessary for normalization of GH secretory status after
treatment with stereotactic radiosurgery, as reported by
Landolt et al. in a retrospective analysis [86]. This study
of 31 patients treated with gamma knife irradiation sug-
gests that octreotide acts in a radioprotective manner
on GH-secreting adenomas and is thus counterproduc-
tive when given concurrenty with radiotherapy. Nine pa-
tients treated with s.c. or LAR octreotide at the time of
radiation application reached normal IGF-I or GH only
after a significantly longer interval, as compared with
those patients not treated with anti-secretory medica-
tions at the time of irradiation. Randomized, prospec-
tive studies will be necessary to support or refute these
findings.
Multiple side effects, most of which are related to
the presence of somatostatin receptors in the gastroin-
testinal tract, may accompany the use of somatostatin
analogs. These side effects are mostly mild to mod-
erate and are usually transient, although they can be
more serious. In a report of 103 patients treated with
s.c. octreotide, Newman et al. [87] reported diarrhea,
nausea, abdominal discomfort, and loosened stools,
though these typically resolved within 3 months of treat-
ment. Though no patient developed cholecystitis, one
of every five patients with normal ultrasound examina-
tions at baseline developed gallbladder sludge, and an-
other one fourth developed asymptomatic cholelithiasis
[87].
Carbohydrate metabolism may be altered by somato-
statin analog therapy by virtue of the suppression of in-
sulin and glucagon secretion, though these concerns do
not appear to be of major consequence during surveil-
lance lasting 3 to 4 years. In a study of 36 patients fol-
lowed for up to 24 months while on octreotide LAR
therapy [88], after 3 months, mean fasting serum in-
sulin levels had decreased from 17.7 mU/L to 10.5 mU/L,
while fasting glucose levels increased slightly from
95 mg/dL to 106 mg/dL. No difference, however, was
found in serum fasting glucose concentrations after 12–
24 months of treatment. In another study of 22 patients
followed for an average of 41 months, glucose tolerance
improved in 5 patients; new glucose intolerance devel-
oped in 4 patients while GH levels were improving or
unchanged [89]. Whether longer-term treatment with so-
matostatin analogs independently increases the risk for
development of type 2 diabetes mellitus is not known.
The yearly follow-up of glucose tolerance and of fasting
glucose levels in patients being treated with octreotide
or lanreotide is a sensible precaution.
The efficacy of somatostatin analogs in subdu-
ing GH hypersecretion has renewed attention on the
role of medical therapy for the primary treatment of
acromegaly, and two multicenter studies have been en-
couraging in this regard. Bevan et al. examined the ef-
fects of octreotide as primary treatment in 27 patients
with acromegaly, of whom 20 had macroadenomas [90].
Patients were initially given s.c. octreotide 100–200 mcg
t.i.d. for 24 weeks, during which time serum IGF-I was
normalized in 33% of patients, while nadir GH was re-
duced to under 2 ng/mL in 38%. During an additional
24 weeks in which 15 patients were continued on oc-
treotide LAR 20–30 mg i.m. every 4 weeks, IGF-I reverted
to normal in 53%, while nadir GH fell to less than 2 ng/mL
in 79% of patients. Impressively, tumor size was reduced
by more than 10% in all patients save one. Median tumor
volume shrinkage in macroadenomas was 43% during
s.c. octreotide, while microadenomas were reduced by
a median of 49%. A further overall median tumor vol-
ume decrease of 24% was seen during octreotide LAR
therapy, and tumor shrinkage continued throughout the
year-long study such that 73% of patients showed tu-
mor volume reduction greater than 30%. The authors
noted that patients with pre-treatment GH levels less
than 20 ng/mL stood the best chance of having normal-
ization of GH/IGF-I levels together with substantial tu-
mor volume reduction [90]. Newman et al. published a
6-month study of 26 previously untreated acromegaly
patients, in whom s.c. octreotide was as effective in
reducing GH and IGF-I as it was in 81 patients with
persistent GH-hypersecretion following surgery and/or
radiotherapy, though tumor shrinkage was observed in
only 6 of 13 patients [91]. Other studies also attest to
the utility of SST analogs in the primary treatment of
acromegaly [83,84,92]. The cost of life-long treatment
with these drugs weighs against their use as primary
treatment, especially in the case of pituitary microade-
nomas where the probability of surgical cure is high,
or even for macroadenomas confined to the sella which
might be resected in toto. It appears that use of these
agents as primary treatment, in lieu of surgery, is best
considered when the possibility of surgical cure is low,
as in patients with large, invasive macroadenomas or
where surgery is contraindicated, or declined by the pa-
tient. However, patients with large tumors and serum
GH levels of greater than 20–30 ng/mL prior to treatment
are also unlikely to have a satisfactory response to so-
matostatin analogs as primary therapy. They, as well as
those patients harboring large, aggressive, grossly inva-
sive tumors that are unlikely to respond well to either
treatment alone, are probably best served by surgical
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debulking at the hands of an experienced pituitary sur-
geon, followed by somatostatin analog therapy.
Growth Hormone Receptor
Antagonist Therapy
Pegvisomant (Somavert©R , Pharmacia Corp., Peapack,
New Jersey, USA), the first growth hormone receptor
(GHR) antagonist, is expected to join the medical arma-
mentarium of acromegaly treatment in 2003. By nature
of the prevention of post-GH receptor signal transduc-
tion, pegvisomant represents a novel treatment modality
and a new paradigm in the management of acromegaly;
and is exemplary of the clinical application of genetic
engineering. It conveys an advantage over anti-secretory
drugs in being independent of tumor expression of SST
or D2 receptors, and has been extraordinarily efficacious
in normalizing serum IGF-I in two published studies.
Blockade of the physiological action of GH at the cellular
level occurs through the use of a modified GH molecule,
a competitive antagonist of the GH-receptor which pre-
vents GH-induced transcription of IGF-I genes.
The elucidation of the mechanism of interaction be-
tween GH and its receptor [93,94] preceded the purpose-
ful design of the GHR antagonist [95,96]. Human growth
hormone is a polypeptide chain of 191 amino acid length,
with a tertiary structure of four alpha-helices in a bun-
dled core. The GH molecule is bivalent, capable of inter-
facing sequentially with two GHRs at separate binding
domains (sites I and II) [97], thereby inducing the dimer-
ization of two GHR molecules at the target cell surface.
Fifty to sixty percent of GH in serum is unbound by the
GH-binding protein [98], and is free to bind the GHR.
When GH contacts a single GHR molecule on the cell
surface, the two form the GH-GHR complex via binding
at site I. The GH-GHR complex is then joined by a second
cell-surface GHR molecule [92,99,100]; the dimerization
of two GHR molecules is the final necessary event for
activation of signal transduction, with transcription of
the genes coding for IGF-I following sequentially.
Pegvisomant is a genetically modified GH molecule
with nine amino acid substitutions within binding sites
I and II that result in two important differences from
the action of native GH [101,102]. Amino acid substitu-
tions in binding site I afford pegvisomant a 30-fold in-
creased affinity over native GH [93,101]. After the joining
of the GHR antagonist and the first GH receptor, GHR
dimerization is prevented by the presence of a long side-
chain amino acid substituted within site II of pegviso-
mant [102]. The addition of 4 or 5 polyethylene glycol
moieties enhances the competitive advantage of pegvi-
somant over native GH by prolonging its serum half-life
to roughly 72 hours, and also lowers immunogenic po-
tential [103,104].
Outcomes of a randomized, double blind, placebo-
controlled multicenter trial of pegvisomant in 112
acromegaly patients were first published in 2000 [105].
Pegvisomant resulted in normalization of IGF-I in 54, 81
and 89 percent of patients given daily doses of 10, 15 and
20 mg, respectively; demonstrating a dose-dependent
effect on IGF-I reduction. Significant improvement in
symptom complexes was achieved in patients treated
with pegvisomant 15 mg and 20 mg daily. Van der Lely
et al. reported normalization of IGF-I in 97% of patients
treated with pegvisomant in doses up to 40 mg daily in
a subsequent analysis of long-term efficacy and safety
of 160 patients observed over a mean follow-up of 14
months [106]. The normalization of IGF-I was associated
with a fall in mean fasting serum insulin concentrations
and in mean fasting glucose at 6 months of follow-up,
indicating a positive affect on the insulin resistance and
hyperinsulinemia of acromegaly [106].
Pegvisomant was well tolerated in both studies,
though new serologic evidence of asymptomatic hepa-
tocellular injury without hepatobiliary involvement was
seen in a total of three patients shortly after the initiation
of pegvisomant [105,106]. Aminotransaminase levels re-
turned to normal in all three patients when the drug was
withdrawn. Antibodies to GH or to pegvisomant were
detected in up to one fifth of patients, though no patient
developed tachyphylaxis. Serum GH concentrations in-
creased during pegvisomant therapy, presumably a re-
sult of the loss of IGF-I negative feedback, which raises
the possibility of tumor enlargement due to GHR an-
tagonist treatment. In both studies, magnetic resonance
imaging of the pituitary before and after pegvisomant
treatment was carried out. Two patients with aggres-
sive tumors showed tumor enlargement during therapy,
though one may have enlarged during a 5-month period
on octreotide alone. A later sub-analysis of MRI data
from 131 patients reported by van der Lely et al. ac-
counted for tumor volume before and after pegvisomant
and stratified tumor response according to prior treat-
ment scheme [107]. After a mean follow-up of one year,
mean tumor volume decreased by 0.04 ± 0.06 cm3 from
2.38 cm3 (range, 0.11–15.18 cm3) at baseline. No signif-
icant change in tumor volume in relation to baseline or
other treatment groups could be demonstrated.
Pegvisomant’s dependence on the disruption of in-
teraction between GH and peripheral tissue as a means
of disease control provides a fundamental distinction to
the GH-suppressive medications. GH receptor antago-
nist therapy will be a welcome addition to the treatment
options for the control of persistently elevated serum
IGF-I in acromegaly patients not adequately treated by
surgery, radiation, and/or anti-secretory therapy. Pegvi-
somant promises a very high rate of normalization of
IGF-I in patients with acromegaly. The liver enzyme el-
evation seen in a small number of patients indicates
the need for vigilance in the setting of known liver dis-
ease, and monitoring of liver enzymes should be un-
dertaken in all patients treated, though the duration
of surveillance necessary remains to be determined.
Monitoring for potential tumor enlargement with peri-
odic MRI scans is also warranted. The dose of pegvi-
somant should be titrated to target serum IGF-I levels
within normal age- and sex-controlled ranges to achieve
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adequate disease control. Pegvisomant’s predictable ef-
fect on IGF-I may allow for future targeting of a precise
quadrant within the normal IGF-I range to achieve op-
timal disease control while avoiding symptoms of GH
deficiency. Studies are also needed to determine the ap-
propriate use of pegvisomant in the primary treatment
of acromegaly, in children with gigantism, in pregnant
women and in potential combination with somatostatin
analogues and/or dopamine agonists.
Estrogen Therapy
Early data by Clemmons et al. have shown that estro-
gen lowers serum IGF-I in patients with acromegaly and
effects beneficial clinical and biochemical responses
[108], due to the effect of estrogen on hepatic and, pre-
sumably, extrahepatic IGF-I biosynthesis [109]. This ap-
proach is, for obvious reasons, impractical in men, al-
though we successfully employed it in several women
with mild residual disease. The selective estrogen recep-
tor modulators tamoxifen and raloxifene have recently
been shown to have a similar effect [110,111], and this
approach may prove to be useful in selected groups of
patients.
Summary
Most patients with acromegaly present with tumors that
cannot be completely resected, and require further treat-
ment for disease management following pituitary mi-
crosurgery. Radiotherapy requires several years to con-
trol GH-hypersecretion, and the discouraging adverse
effect of hypopituitarism occurs in about half of pa-
tients by the time GH secretion is subdued. Meanwhile,
the range of products available for the medical treat-
ment of acromegaly has developed into an adaptable
assortment; and new additions on the horizon promise
to broaden the array of treatment options.
Growth hormone suppression with cabergoline is
well tolerated and remains a worthwhile strategy, partic-
ularly in patients with concurrent hyperprolactinemia.
Still, not more than half of such patients achieve a nor-
malized IGF-I on cabergoline, and the success rate with
GH-excess alone is even less. The long-acting somato-
statin analogs lanreotide SR and octreotide LAR set the
standard for the medical treatment of acromegaly in the
pre-GHR antagonist era as a result of their superior effi-
cacy in comparison with the dopamine agonists. A ma-
jority of patients may have significant tumor shrinkage
with SST analogs, though this effect cannot always be
counted on, and at least one third of patients do not have
a satisfactory biochemical response.
Pharmacologic blockade of the GH receptor is about
to emerge as a highly effective secondary treatment of
acromegaly in the majority of patients requiring aggres-
sive postoperative therapy. Pegvisomant renders incon-
sequential the GH hypersecretion of residual tumor cells
refractory to GH-suppressive therapy, and as such has
highlighted the recognition of serum IGF-I concentra-
tion as the truest marker of disease status in acromegaly.
The normalization of circulating IGF-I, as the foremost
biochemical goal of the treatment of acromegaly, is
about to be brought within reach for essentially all pa-
tients with this debilitating disease.
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